Fulvestrant: all 236 studies that test it
Page 2 of 3. Open to participants first (47), then studies with results posted, then the rest; newest registration first within each.
- Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung CancerTerminatedNCT00592007Phase 2Results posted
- Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor FailureCompletedNCT00570921Phase 2Results posted
- Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast CancerCompletedNCT00570323Phase 2Results posted
- Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs AnastrozoleTerminatedNCT00543127Phase 3Results posted
- Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast CancerCompletedNCT00534417Phase 2Results posted
- Fulvestrant in Hormone Refractory Prostate CancerCompletedNCT00476645Phase 2Results posted
- Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast CancerCompletedNCT00423917Phase 2Results posted
- Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast CancerCompletedNCT00405938Phase 2Results posted
- Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast CancerCompletedNCT00357110Phase 2Results posted
- Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.CompletedNCT00334295Phase 2Results posted
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mgCompletedNCT00313170Phase 2Results posted
- A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg (Plus 250mg Loading Regimen) and 500mgCompletedNCT00305448Phase 2Results posted
- Faslodex in McCune-Albright SyndromeCompletedNCT00278915Phase 2Results posted
- A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast CancerCompletedNCT00274469Phase 2Results posted
- Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast CancerCompletedNCT00259090Phase 2Results posted
- Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination TherapyCompletedNCT00256698Phase 3Results posted
- Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase InhibitorsCompletedNCT00253422Phase 3Results posted
- Fulvestrant in Treating Patients With Recurrent Prostate CancerTerminatedNCT00217464Phase 2Results posted
- Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast CancerCompletedNCT00201864Phase 2Results posted
- A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)TerminatedNCT00183963Phase 2Results posted
- Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast CancerTerminatedNCT00138125Phase 2Results posted
- Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.Active, not recruitingNCT00099437Phase 3Results posted
- Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT00082810Phase 2Results posted
- S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast CancerCompletedNCT00075764Phase 3Results posted
- Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast CancerCompletedNCT00057941Phase 2Results posted
- Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial CancerStatus unknownNCT00006903Phase 2Results posted
- A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.Active, not recruitingNCT07557004Phase 1
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsActive, not recruitingNCT07038369Phase 1
- A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingNCT06764186Phase 3
- Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerActive, not recruitingNCT06702618Phase 2
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive, not recruitingNCT06635447Phase 3
- Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Active, not recruitingNCT06506955Phase 2/3
- Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)TerminatedNCT06408168Phase 2
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerActive, not recruitingNCT06110793Phase 1/2
- Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic StudyCompletedNCT06074757Phase 1
- [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingNCT05826964Phase 2
- Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast CancerActive, not recruitingNCT05574881Phase 1/2
- This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.Status unknownNCT05438810Phase 3
- SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)Active, not recruitingNCT05392608Phase 2
- Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2
- CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerActive, not recruitingNCT05251714Phase 1/2
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 InhibitorsStatus unknownNCT05191914Phase 4
- Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCWithdrawnNCT05191004Phase 1/2
- A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingNCT05154487Phase 2
- A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast CancerActive, not recruitingNCT05077449Phase 3
- Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedNCT05063786Phase 3
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Phase 3
- Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast CancerStatus unknownNCT05047848Not applicable
- Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+GoserelinStatus unknownNCT05004142Phase 2
- Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast CancerStatus unknownNCT04999540Phase 2
- Fulvestrant + Neratinib In Breast CancerWithdrawnNCT04901299Phase 2
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3
- A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast CancerCompletedNCT04796623Phase 2
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingNCT04567420Phase 2
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
- A Phase I/II Study of XZP-3287 in Metastasis Solid TumorsActive, not recruitingNCT04539496Phase 1/2
- Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast CancerActive, not recruitingNCT04524000Phase 2
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
- Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
- A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast CancerStatus unknownNCT04355520Phase 1/2
- Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast CancerCompletedNCT04352777Phase 2
- Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
- Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.Active, not recruitingNCT04053322Phase 2
- Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )Status unknownNCT04033172Phase 2
- FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia StudyCompletedNCT03926936Phase 2
- WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 InhibitorCompletedNCT03854903Phase 1
- A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1
- Fulvestrant in Metastatic Breast CancerStatus unknownNCT03591549Phase 4
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerStatus unknownNCT03560856Phase 2
- Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous CarcinomaActive, not recruitingNCT03531645Phase 2
- Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsActive, not recruitingNCT03393845Phase 2
- Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM AdministrationCompletedNCT03324061Phase 1
- HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceTerminatedNCT03322215Phase 2
- Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast CancerCompletedNCT03308201Phase 1
- Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyTerminatedNCT03220178Phase 4
- The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerStatus unknownNCT03202862Phase 2
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- Metformin and Simvastatin in Addition to FulvestrantStatus unknownNCT03192293Phase 2
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknownNCT03182634Phase 2
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
- G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownNCT02983071Phase 1/2
- SFX-01 in the Treatment and Evaluation of Metastatic Breast CancerCompletedNCT02970682Phase 2
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2
- Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female SubjectsCompletedNCT02795039Phase 1
- Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT02760030Phase 2
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorActive, not recruitingNCT02738866Phase 2
- A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerCompletedNCT02684032Phase 1
- Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer PatientsStatus unknownNCT02646735Phase 2
- Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerStatus unknownNCT02626507Phase 1
- Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast CancerStatus unknownNCT02404051Phase 3
- Phase I Study of the Combination of MLN9708 and FulvestrantTerminatedNCT02384746Phase 1
- Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC PatientsStatus unknownNCT02383030Phase 3